GSK plc
GSK NYSEHealthcare ★★★★★Latest Earnings
Date
Jul 28, 2026
ET
EPS Est.
1.27
EPS Actual
1.36
Revenue Est.
$11.02B
Revenue Actual
$11.18B
Next Earnings Report
Date
Oct 28, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
1.37
Revenue Est.
$11.88B
Company Overview
GSK plc (ticker GSK) is listed on NYSE with a market cap of about $105B. Its next earnings report (FY2026 Q3) is expected on Oct 28, 2026 (ET), Pre-market, with consensus EPS of 1.37. In the last 15 reported quarters, EPS beat consensus estimates 15 times.
Actual EPS TrendRecently15Term · Nov 2, 2022 → Jul 28, 2026
Nov 2, 2022Range: 0.59 ~ 1.48Jul 28, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 28, 2026 | -- | 1.27 | 1.36 | $11.02B | $11.18B |
| Apr 29, 2026 | -- | 1.16 | 1.24 | $10.23B | $10.3B |
| Feb 4, 2026 | -- | 0.64 | 0.68 | $11.41B | $11.78B |
| Oct 29, 2025 | -- | 1.26 | Above forecast↑1.48 | $11.04B | $11.32B |
| Jul 30, 2025 | -- | 1.12 | 1.23 | $10.5B | $10.61B |
| Apr 30, 2025 | -- | 1.08 | 1.13 | $9.72B | $10.04B |
| Feb 5, 2025 | -- | 0.44 | Above forecast↑0.59 | $9.54B | $10.16B |
| Oct 30, 2024 | -- | 1.16 | 1.27 | $10.52B | $10.42B |
| Jul 31, 2024 | -- | 1.00 | 1.09 | $9.57B | $10.13B |
| May 1, 2024 | -- | 0.91 | Above forecast↑1.09 | $8.89B | $9.2B |
| Nov 1, 2023 | -- | 1.09 | Above forecast↑1.26 | $9.37B | $9.88B |
| Jul 26, 2023 | -- | 0.85 | 0.97 | $8.78B | $9.28B |
| Apr 26, 2023 | -- | 0.85 | 0.90 | $8.07B | $8.67B |
| Feb 1, 2023 | -- | 0.59 | 0.64 | $8.9B | $9.09B |
| Nov 2, 2022 | -- | 0.90 | Above forecast↑1.09 | $8.31B | $8.97B |
Original Filings (SEC)
6-K2026-08-18 ↗
6-K2026-08-13 ↗
6-K2026-08-11 ↗
6-K2026-08-03 ↗
6-K2026-07-30 ↗
6-K2026-07-28 ↗
6-K2026-07-28 ↗
6-K2026-07-28 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
